Archive Search

Pages

United Therapeutics Corp. (NASDAQ:UTHR) fell $12.79 to $122.17, losing $553 million in market cap, after reporting during its 4Q17 earnings call Wednesday that RemoSynch, the implantable drug infusion system for Remodulin treprostinil, will launch "within...

The Trump Administration outlined a plan to reform Medicaid and Medicare and reduce "free-riding" by foreign markets in the joint Economic Report of the President and Annual Report of the Council of Economic Advisers released...

In a paper published in Nature, a group from the Max Planck Institute and Harvard University describe a method to fluorinate a wider array of aromatic carbon-hydrogen bonds than currently available methods allow. The method...

Life sciences investment firm Arix Bioscience plc (LSE:ARIX) partnered with Ipsen Group (Euronext:IPN; Pink:IPSEY) to create new companies focused on developing and commercializing "innovative therapies" in undisclosed indications. Arix said it could not provide details...

In response to a request for opinion on innovative pricing models from the European Commission, an expert panel said it is "unlikely that a single payment model will be optimal for all situations." The panel...

Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said remestemcel-L (MSC-100-IV) met the primary endpoint in a Phase III trial to treat steroid-refractory acute graft-versus-host disease (GvHD). The company said full data from the trial, which are expected next...

The Australian government passed legislation that mandates steeper price cuts to drugs on the country's Pharmaceutical Benefits Scheme (PBS). The law increases the statutory price reduction applied to a drug upon approval of the first...

Merck & Co. Inc. (NYSE:MRK) will acquire oncolytic immunotherapy company Viralytics Ltd. (ASX:VLA; OTCQX:VRACY) for A$1.75 per share, or A$502 million ($398 million). The price is a 182% premium to Viralytics’ close of A$0.62 on...